[Skip to Content]
[Skip to Content Landing]
November 8, 2006

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis

Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296(18):2201-2204. doi:10.1001/jama.296.18.2201-b

To the Editor: Dr Bongartz and colleagues1 reported the results of a meta-analysis of randomized clinical trials of the TNF-blocking monoclonal antibodies infliximab and adalimumab, finding an increased risk of serious infections and malignancies associated with their use. However, previous meta-analyses of randomized clinical trials of infliximab and adalimumab were conducted at the request of the US Food and Drug Administration (FDA), leading to revised product labeling for infliximab in September 2005 and for adalimumab in October 2005.